QL2107

QL2107 is an investigational agent whose form is not stated in the registry developed by Qilu Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 200mg on day 1 of each 21-day cycle of the study. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06754644 (A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC), in non-small-cell lung cancer. The largest, NCT06754644, plans to enrol 808 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.